Agilent Technologies announces takeover of Luxcel Biosciences

Agilent Technologies has announced the acquisition of Luxcel Biosciences, an Ireland-based developer of real-time fluorescence plate reader-based in vitro cell assay kits.

This acquisition will expand Agilent's cell analysis portfolio with the addition of a number of easy-to-use assay kits that are compatible with industry standard plate-readers. It builds on the progress Agilent has made in this sector since entering it with the purchase of Seahorse Bioscience in 2015.

Luxcel was founded in 2002 as a spin-out from University College Cork, and has 12 employees. The Luxcel team will remain in Cork and will form a dedicated sensor chemistries and bioassay solutions group within Agilent's cell analysis division.

Its range of in vitro cell-based assay kits and solutions target cell metabolism, drug safety and toxicity, as well as hypoxia and oxidative stress, to help elucidate the role of cell metabolism across areas such as cancer, metabolic disorders, cardiovascular disease, immunology and infectious disease.

Todd Christian, general manager of Agilent's cell analysis division, said: "With this acquisition, we further extend our leadership in live-cell, kinetic assays accelerating our expansion into pharmaceutical and biopharma discovery and in vitro toxicology screening applications."

With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.